SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
– Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors –
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced an upcoming poster presentation at the 2019 ASCO Annual Meeting being held in Chicago, May 31 – June 4, 2019.
Data will be presented from the Phase 1a/1b study of FPA150, which is a first-in-class B7-H4 antibody. The Phase 1a dose escalation portion of the study is being conducted in patients with advanced solid tumors and the Phase 1b expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.
Here are the details of the upcoming poster presentation:
|Poster Title:||Phase 1a/1b Study of First-in-class B7-H4 Antibody, FPA150 as Monotherapy in Patients with Advanced Solid Tumors|
|Poster Session:||Developmental Immunotherapy and Tumor Immunobiology|
|Date & Time:||Saturday, June 1, 2019, 8:00 – 11:00am|
The poster abstracts will be available on May 15, 2019 at 5:00 PM EST at the ASCO Meeting Library and the posters can be found on Five Prime Therapeutics’ Scientific Publications page after presentation at the conference.
FPA150 is a novel, fully human, afucosylated monoclonal antibody targeting B7-H4. B7-H4 expression is observed in multiple solid tumors, including breast and gynecologic cancers. FPA150 is designed with a dual mechanism of action: blocking the T cell checkpoint activity of B7-H4 as well as enhanced ADCC against tumor cells expressing B7-H4.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com or follow us on LinkedIn, Twitter and Facebook.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.